Keith D Lindor

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7682195/publications.pdf

Version: 2024-02-01

259 papers	29,464 citations	3325 91 h-index	5101 166 g-index
300 all docs	300 docs citations	300 times ranked	11483 citing authors

#	Article	IF	Citations
1	Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology, 1999, 30, 1356-1362.	3.6	1,453
2	Primary biliary cirrhosis. Hepatology, 2009, 50, 291-308.	3.6	1,020
3	A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis. New England Journal of Medicine, 2016, 375, 631-643.	13.9	817
4	Immunoglobulin G4â€“Associated Cholangitis: Clinical Profile and Response to Therapy. Gastroenterology, 2008, 134, 706-715.	0.6	807
5	Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: Results of a randomized trial. Hepatology, 2004, 39, 770-778.	3.6	651
6	Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis. Gastroenterology, 1997, 113, 884-890.	0.6	608
7	High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis. Hepatology, 2009, 50, 808-814.	3.6	603
8	Ursodiol for Primary Sclerosing Cholangitis. New England Journal of Medicine, 1997, 336, 691-695.	13.9	569
9	Risk factors and comorbidities in primary biliary cirrhosis: A controlled interview-based study of 1032 patients. Hepatology, 2005, 42, 1194-1202.	3.6	560
10	Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis. Gastroenterology, 2003, 124, 889-893.	0.6	534
11	Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases. Hepatology, 2019, 69, 394-419.	3.6	507
12	Incidence and Risk Factors for Cholangiocarcinoma in Primary Sclerosing Cholangitis. American Journal of Gastroenterology, 2004, 99, 523-526.	0.2	503
13	Primary biliary cirrhosis. Lancet, The, 2015, 386, 1565-1575.	6.3	502
14	Primary sclerosing cholangitis. Lancet, The, 2013, 382, 1587-1599.	6.3	484
15	Efficacy of Obeticholic Acid in Patients With Primary Biliary Cirrhosis and Inadequate Response to Ursodeoxycholic Acid. Gastroenterology, 2015, 148, 751-761.e8.	0.6	470
16	Ursodeoxycholic acid in the treatment of primary biliary cirrhosis. Gastroenterology, 1994, 106, 1284-1290.	0.6	457
17	ACG Clinical Guideline: Primary Sclerosing Cholangitis. American Journal of Gastroenterology, 2015, 110, 646-659.	0.2	400
18	Levels of Alkaline Phosphatase and Bilirubin Are Surrogate End Points of Outcomes of Patients With Primary Biliary Cirrhosis: An International Follow-up Study. Gastroenterology, 2014, 147, 1338-1349.e5.	0.6	365

#	Article	IF	Citations
19	Pathogenesis of Primary Sclerosing Cholangitis and Advances in Diagnosis and Management. Gastroenterology, 2013, 145, 521-536.	0.6	359
20	Patient Age, Sex, and Inflammatory Bowel Disease Phenotype Associate With Course of Primary Sclerosing Cholangitis. Gastroenterology, 2017, 152, 1975-1984.e8.	0.6	355
21	Development and Validation of a Scoring System to Predict Outcomes of Patients With Primary Biliary Cirrhosis Receiving Ursodeoxycholic Acid Therapy. Gastroenterology, 2015, 149, 1804-1812.e4.	0.6	330
22	Utility of serum tumor markers, imaging, and biliary cytology for detecting cholangiocarcinoma in primary sclerosing cholangitis. Hepatology, 2008, 48, 1106-1117.	3.6	329
23	Elevated Serum IgG4 Concentration in Patients with Primary Sclerosing Cholangitis. American Journal of Gastroenterology, 2006, 101, 2070-2075.	0.2	327
24	Epidemiology and natural history of primary biliary cirrhosis in a U.S. community. Gastroenterology, 2000, 119, 1631-1636.	0.6	321
25	Primary biliary cirrhosis. Lancet, The, 2003, 362, 53-61.	6.3	306
26	The Value of Serum CA 19-9 in Predicting Cholangiocarcinomas in Patients with Primary Sclerosing Cholangitis. Digestive Diseases and Sciences, 2005, 50, 1734-1740.	1.1	300
27	A Revised Natural History Model for Primary Sclerosing Cholangitis. Mayo Clinic Proceedings, 2000, 75, 688-694.	1.4	285
28	A Revised Natural History Model for Primary Sclerosing Cholangitis. Mayo Clinic Proceedings, 2000, 75, 688-694.	1.4	280
29	Cancer surveillance in patients with primary sclerosing cholangitis. Hepatology, 2011, 54, 1842-1852.	3.6	248
30	Primary sclerosing cholangitis. Hepatology, 1999, 30, 325-332.	3.6	245
31	Immunoglobulin G4 associated cholangitis: Description of an emerging clinical entity based on review of the literature. Hepatology, 2007, 45, 1547-1554.	3.6	224
32	High-Dose Ursodeoxycholic Acid Is Associated With the Development of Colorectal Neoplasia in Patients With Ulcerative Colitis and Primary Sclerosing Cholangitis. American Journal of Gastroenterology, 2011, 106, 1638-1645.	0.2	223
33	Primary sclerosing cholangitis in children: A long-term follow-up study. Hepatology, 2003, 38, 210-217.	3.6	218
34	High-Dose Ursodeoxycholic Acid as a Therapy for Patients With Primary Sclerosing Cholangitis. American Journal of Gastroenterology, 2001, 96, 1558-1562.	0.2	215
35	Randomised clinical trial: vancomycin or metronidazole in patients with primary sclerosing cholangitis â€•a pilot study. Alimentary Pharmacology and Therapeutics, 2013, 37, 604-612.	1.9	212
36	Effects of ursodeoxycholic acid on survival in patients with primary biliary cirrhosis. Gastroenterology, 1996, 110, 1515-1518.	0.6	209

#	Article	IF	Citations
37	Long-term ursodeoxycholic acid delays histological progression in primary biliary cirrhosis. Hepatology, 1999, 29, 644-647.	3.6	209
38	A Controlled Trial of Cyclosporine in the Treatment of Primary Biliary Cirrhosis. New England Journal of Medicine, 1990, 322, 1419-1424.	13.9	208
39	Combined analysis of the effect of treatment with ursodeoxycholic acid on histologic progression in primary biliary cirrhosis. Journal of Hepatology, 2003, 39, 12-16.	1.8	199
40	REVIEW: Nonalcoholic steatohepatitis. Journal of Gastroenterology and Hepatology (Australia), 1997, 12, 398-403.	1.4	198
41	Balloon Dilation Compared To Stenting of Dominant Strictures in Primary Sclerosing Cholangitis. American Journal of Gastroenterology, 2001, 96, 1059-1066.	0.2	193
42	Small-duct primary sclerosing cholangitis: A long-term follow-up study. Hepatology, 2002, 35, 1494-1500.	3.6	189
43	In primary sclerosing cholangitis, gallbladder polyps are frequently malignant. American Journal of Gastroenterology, 2002, 97, 1138-1142.	0.2	175
44	Time course of histological progression in primary biliary cirrhosis. Hepatology, 1996, 23, 52-56.	3.6	171
45	Oral budesonide in the treatment of patients with primary biliary cirrhosis with a suboptimal response to ursodeoxycholic acid. Hepatology, 2000, 31, 318-323.	3.6	171
46	Bone disease in primary biliary cirrhosis: independent indicators and rate of progression. Journal of Hepatology, 2001, 35, 316-323.	1.8	170
47	Hypercholesterolemia and atherosclerosis in primary biliary cirrhosis: What is the risk?. Hepatology, 1992, 15, 858-862.	3.6	168
48	Utilization of the Mayo risk score in patients with primary biliary cirrhosis receiving ursodeoxycholic acid. Liver International, 1999, 19, 115-121.	1.9	168
49	Metabolic and nutritional considerations in nonalcoholic fatty liver. Hepatology, 2000, 32, 3-10.	3.6	166
50	Primary biliary cirrhosis with additional features of autoimmune hepatitis: Response to therapy with ursodeoxycholic acid. Hepatology, 2002, 35, 409-413.	3.6	160
51	Long-term survival and impact of ursodeoxycholic acid treatment for recurrent primary biliary cirrhosis after liver transplantation. Liver Transplantation, 2007, 13, 1236-1245.	1.3	159
52	Long-term outcomes of positive fluorescence in situ hybridization tests in primary sclerosing cholangitis. Hepatology, 2010, 51, 174-180.	3.6	159
53	Overlap of autoimmune hepatitis and primary sclerosing cholangitis: an evaluation of a modified scoring systemNote. Journal of Hepatology, 2000, 33, 537-542.	1.8	157
54	Overlap of autoimmune hepatitis and primary sclerosing cholangitis: an evaluation of a modified scoring system. Journal of Hepatology, 2000, 33, 537-542.	1.8	152

#	Article	IF	Citations
55	Cost-effectiveness of ultrasound-guided liver biopsy. Hepatology, 1998, 27, 1220-1226.	3.6	150
56	Ursodeoxycholic Acid Delays the Onset of Esophageal Varices in Primary Biliary Cirrhosis. Mayo Clinic Proceedings, 1997, 72, 1137-1140.	1.4	149
57	Ursodeoxycholic acid therapy and liver transplant-free survival in patients with primary biliary cholangitis. Journal of Hepatology, 2019, 71, 357-365.	1.8	148
58	Is There A Role for Liver Biopsy in Primary Sclerosing Cholangitis?. American Journal of Gastroenterology, 2003, 98, 1155-1158.	0.2	146
59	Overlap of Autoimmune Hepatitis and Primary Biliary Cirrhosis: Long-Term Outcomes. American Journal of Gastroenterology, 2007, 102, 1244-1250.	0.2	139
60	Stratification of hepatocellular carcinoma risk in primary biliary cirrhosis: a multicentre international study. Gut, 2016, 65, 321-329.	6.1	139
61	Oral budesonide in the treatment of primary sclerosing cholangitis. American Journal of Gastroenterology, 2000, 95, 2333-2337.	0.2	138
62	Alendronate improves bone mineral density in primary biliary cirrhosis: A randomized placebo-controlled trial. Hepatology, 2005, 42, 762-771.	3.6	138
63	Alkaline phosphatase normalization is associated with better prognosis in primary sclerosing cholangitis. Digestive and Liver Disease, 2011, 43, 309-313.	0.4	138
64	Nutritional and metabolic considerations in the etiology of nonalcoholic steatohepatitis. Digestive Diseases and Sciences, 2001, 46, 2347-2352.	1.1	136
65	Ursodeoxycholic acid as adjunctive therapy for problematic type 1 autoimmune hepatitis: A randomized placebo-controlled treatment trial. Hepatology, 1999, 30, 1381-1386.	3.6	133
66	Biochemical and immunologic effects of rituximab in patients with primary biliary cirrhosis and an incomplete response to ursodeoxycholic acid. Hepatology, 2012, 55, 512-521.	3.6	130
67	Antimitochondrial antibody-negative primary biliary cirrhosis. American Journal of Gastroenterology, 1995, 90, 247-9.	0.2	127
68	Increased prevalence of antimitochondrial antibodies in first-degree relatives of patients with primary biliary cirrhosis. Hepatology, 2007, 46, 785-792.	3.6	125
69	Changing nomenclature for PBC: From â€˜cirrhosisâ€™ to â€˜cholangitisâ€™. Hepatology, 2015, 62, 1620-1622.	3.6	125
70	The relative role of the child-pugh classification and the mayo natural history model in the assessment of survival in patients with primary sclerosing cholangitis. Hepatology, 1999, 29, 1643-1648.	3.6	124
71	Overlap of autoimmune hepatitis and primary biliary cirrhosis: an evaluation of a modified scoring system. American Journal of Gastroenterology, 2002, 97, 1191-1197.	0.2	120
72	Bone disease in patients with primary sclerosing cholangitis: prevalence, severity and prediction of progression. Journal of Hepatology, 1998, 29, 729-735.	1.8	119

#	Article	IF	Citations
73	Primary Sclerosing Cholangitis Associated with Elevated ImmunoglobulinG4: Clinical Characteristics and Response to Therapy. American Journal of Therapeutics, 2011, 18, 198-205.	0.5	119
74	Cost-minimization analysis of MRC versus ERCP for the diagnosis of primary sclerosing cholangitis. Hepatology, 2004, 40, 39-45.	3.6	117
75	The metabolic bone disease of primary sclerosing cholangitis. Hepatology, 1991, 14, 257-261.	3.6	115
76	Recent advances in the development of farnesoid X receptor agonists. Annals of Translational Medicine, 2015, 3, 5.	0.7	115
77	Minocycline in the Treatment of Patients With Primary Sclerosing Cholangitis: Results of a Pilot Study. American Journal of Gastroenterology, 2009, 104, 83-88.	0.2	114
78	Comparison of three doses of ursodeoxycholic acid in the treatment of primary biliary cirrhosis: a randomized trial. Journal of Hepatology, 1999, 30, 830-835.	1.8	112
79	Natural history of pruritus in primary biliary cirrhosis. Clinical Gastroenterology and Hepatology, 2003, 1, 297-302.	2.4	112
80	Primary Sclerosing Cholangitis. Inflammatory Bowel Diseases, 2005, 11, 62-72.	0.9	112
81	Novel therapeutic targets in primary biliary cirrhosis. Nature Reviews Gastroenterology and Hepatology, 2015, 12, 147-158.	8.2	110
82	Many Patients With Primary Sclerosing Cholangitis and Increased Serum Levels of Carbohydrate Antigen 19-9 Do Not Have Cholangiocarcinoma. Clinical Gastroenterology and Hepatology, 2011, 9, 434-439.e1.	2.4	108
83	Fat-soluble vitamin levels in patients with primary biliary cirrhosis. American Journal of Gastroenterology, 2001, 96, 2745-2750.	0.2	106
84	Bone Disease in Patients With Primary Sclerosing Cholangitis. Gastroenterology, 2011, 140, 180-188.	0.6	102
85	Primary Sclerosing Cholangitis Patients With Serial Polysomy Fluorescence In Situ Hybridization Results Are at Increased Risk of Cholangiocarcinoma. American Journal of Gastroenterology, 2011, 106, 2023-2028.	0.2	101
86	Ustekinumab for patients with primary biliary cholangitis who have an inadequate response to ursodeoxycholic acid: A proofâ€ofâ€concept study. Hepatology, 2016, 64, 189-199.	3.6	101
87	Does antimitochondrial antibody status affect response to treatment in patients with primary biliary cirrhosis? Outcomes of ursodeoxycholic acid therapy and liver transplantation. Hepatology, 1997, 26, 22-26.	3.6	100
88	Autoimmune Hepatitisâ€"PBC Overlap Syndrome: A Simplified Scoring System May Assist in the Diagnosis. American Journal of Gastroenterology, 2010, 105, 345-353.	0.2	99
89	Ursodeoxycholic Acid for the Treatment of Primary Biliary Cirrhosis. New England Journal of Medicine, 2007, 357, 1524-1529.	13.9	98
90	Incidence of cancer in primary biliary cirrhosis: The mayo experience. Hepatology, 1999, 29, 1396-1398.	3.6	97

#	Article	IF	Citations
91	Bone disease in primary biliary cirrhosis: Does ursodeoxycholic acid make a difference?. Hepatology, 1995, 21, 389-392.	3.6	95
92	Surveillance for hepatobiliary cancers in patients with primary sclerosing cholangitis. Hepatology, 2018, 67, 2338-2351.	3.6	92
93	Bone disease in primary biliary cirrhosis: does ursodeoxycholic acid make a difference?. Hepatology, 1995, 21, 389-92.	3.6	90
94	B-cell depletion with anti-CD20 ameliorates autoimmune cholangitis but exacerbates colitis in transforming growth factor-Î² receptor II dominant negative mice. Hepatology, 2009, 50, 1893-1903.	3.6	88
95	The combination of prednisone and colchicine in patients with primary sclerosing cholangitis. American Journal of Gastroenterology, 1991, 86, 57-61.	0.2	88
96	A pilot study of pentoxifylline for the treatment of primary sclerosing cholangitis. American Journal of Gastroenterology, 2000, 95, 2338-2342.	0.2	85
97	Changing nomenclature for PBC: From â€˜cirrhosisâ€™ to â€˜cholangitisâ€™. Journal of Hepatology, 2015, 63, 1285-1287.	1.8	85
98	When is liver biopsy needed in the diagnosis of primary biliary cirrhosis?. Clinical Gastroenterology and Hepatology, 2003, 1, 89-95.	2.4	84
99	Serum Lipid and Fat-Soluble Vitamin Levels in Primary Sclerosing Cholangitis. Journal of Clinical Gastroenterology, 1995, 20, 215-219.	1.1	83
100	The combination of ursodeoxycholic acid and methotrexate for patients with primary biliary cirrhosis: The results of a pilot study*1. Hepatology, 1995, 22, 1158-1162.	3.6	81
101	Silymarin in the Treatment of Patients With Primary Biliary Cirrhosis With a Suboptimal Response to Ursodeoxycholic Acid. Hepatology, 2000, 32, 897-900.	3.6	80
102	Clinical significance of serum bilirubin levels under ursodeoxycholic acid therapy in patients with primary biliary cirrhosis. Hepatology, 1999, 29, 39-43.	3.6	79
103	Role of the Microbiota and Antibiotics in Primary Sclerosing Cholangitis. BioMed Research International, 2013, 2013, 1-7.	0.9	79
104	Likelihood of Malignancy in Gallbladder Polyps and Outcomes Following Cholecystectomy in Primary Sclerosing Cholangitis. American Journal of Gastroenterology, 2012, 107, 431-439.	0.2	77
105	Primary sclerosing cholangitis and the microbiota: current knowledge and perspectives on etiopathogenesis and emerging therapies. Scandinavian Journal of Gastroenterology, 2014, 49, 901-908.	0.6	77
106	Etidronate for osteoporosis in primary biliary cirrhosis: a randomized trial. Journal of Hepatology, 2000, 33, 878-882.	1.8	75
107	High-dose ursodeoxycholic acid increases risk of adverse outcomes in patients with early stage primary sclerosing cholangitis. Alimentary Pharmacology and Therapeutics, 2011, 34, 1185-1192.	1.9	75
108	Cancer risk in primary sclerosing cholangitis: Epidemiology, prevention, and surveillance strategies. World Journal of Gastroenterology, 2019, 25, 659-671.	1.4	75

#	Article	IF	Citations
109	Do antinuclear antibodies in primary biliary cirrhosis patients identify increased risk for liver failure?. Clinical Gastroenterology and Hepatology, 2004, 2, 1116-1122.	2.4	74
110	Goals of Treatment for Improved Survival in Primary Biliary Cholangitis: Treatment Target Should Be Bilirubin Within the Normal Range and Normalization of Alkaline Phosphatase. American Journal of Gastroenterology, 2020, 115, 1066-1074.	0.2	74
111	Primary sclerosing cholangitis. Canadian Journal of Gastroenterology & Hepatology, 2008, 22, 689-698.	1.8	73
112	Increasing Prevalence of Primary Biliary Cholangitis and Reduced Mortality With Treatment. Clinical Gastroenterology and Hepatology, 2018, 16, 1342-1350.e1.	2.4	73
113	Oral nicotine in treatment of primary sclerosing cholangitis: a pilot study. Digestive Diseases and Sciences, 1999, 44, 602-607.	1.1	70
114	Mycophenolate Mofetil for the Treatment of Primary Sclerosing Cholangitis. American Journal of Gastroenterology, 2005, 100, 308-312.	0.2	69
115	Characterisation of patients with a complete biochemical response to ursodeoxycholic acid.. Gut, 1995, 36, 935-938.	6.1	68
116	Fibrosis stage is an independent predictor of outcome in primary biliary cholangitis despite biochemical treatment response. Alimentary Pharmacology and Therapeutics, 2019, 50, 1127-1136.	1.9	66
117	Ursodeoxycholic acid and methotrexate for primary sclerosing cholangitis: a pilot study. American Journal of Gastroenterology, 1996, 91, 511-5.	0.2	66
118	Major Hepatic Complications in Ursodeoxycholic Acid-Treated Patients With Primary Biliary Cholangitis: Risk Factors and Time Trends in Incidence and Outcome. American Journal of Gastroenterology, 2018, 113, 254-264.	0.2	64
119	Surveillance for hepatocellular carcinoma in patients with primary biliary cirrhosis. Hepatology, 2008, 48, 1149-1156.	3.6	62
120	Optimizing biochemical markers as endpoints for clinical trials in primary biliary cirrhosis. Liver International, 2012, 32, 790-795.	1.9	62
121	Enhanced autoreactivity of T-lymphocytes in primary sclerosing cholangitis. Hepatology, 1987, 7, 884-888.	3.6	60
122	Clinical and statistical analyses of new and evolving therapies for primary biliary cirrhosis. Hepatology, 1988, 8, 668-676.	3.6	60
123	AGA Clinical Practice Update on Surveillance for Hepatobiliary Cancers in Patients With Primary Sclerosing Cholangitis: Expert Review. Clinical Gastroenterology and Hepatology, 2019, 17, 2416-2422.	2.4	60
124	The combination of ursodeoxycholic acid and methotrexate for patients with primary biliary cirrhosis: The results of a pilot study. Hepatology, 1995, 22, 1158-1162.	3.6	58
125	Interactions between chronic liver disease and inflammatory bowel disease. Inflammatory Bowel Diseases, 1997, 3, 288-302.	0.9	58
126	Review article: the evidence that vancomycin is a therapeutic option for primary sclerosing cholangitis. Alimentary Pharmacology and Therapeutics, 2018, 47, 886-895.	1.9	57

#	Article	IF	Citations
127	Unmet clinical need in autoimmune liver diseases. Journal of Hepatology, 2015, 62, 208-218.	1.8	56
128	Primary sclerosing cholangitis: a review and update on therapeutic developments. Expert Review of Gastroenterology and Hepatology, 2013, 7, 103-114.	1.4	55
129	Prospective Clinical Trial of Rifaximin Therapy for Patients With Primary Sclerosing Cholangitis. American Journal of Therapeutics, 2017, 24, e56-e63.	0.5	55
130	Interactions Between Chronic Liver Disease and Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 1997, 3, 288-302.	0.9	54
131	Effects of Age and Sex of Response to Ursodeoxycholic Acid and Transplant-free Survival in Patients With Primary Biliary Cholangitis. Clinical Gastroenterology and Hepatology, 2019, 17, 2076-2084.e2.	2.4	54
132	Pirfenidone in the treatment of primary sclerosing cholangitis. Digestive Diseases and Sciences, 2002, 47, 157-161.	1.1	53
133	Colon Neoplasms Develop Early in the Course of Inflammatory Bowel Disease and Primary Sclerosing Cholangitis. Clinical Gastroenterology and Hepatology, 2011, 9, 52-56.	2.4	53
134	Clinical trial: randomized controlled study of zidovudine and lamivudine for patients with primary biliary cirrhosis stabilized on ursodiol. Alimentary Pharmacology and Therapeutics, 2008, 28, 886-894.	1.9	52
135	Clinical Predictors for Hepatocellular Carcinoma in Patients With Primary Biliary Cirrhosis. Clinical Gastroenterology and Hepatology, 2007, 5, 259-264.	2.4	51
136	Development of autoimmune hepatitis in primary biliary cirrhosis. Liver International, 2007, 27, 1086-1090.	1.9	51
137	Clinical features and management of primary sclerosing Cholangitis. World Journal of Gastroenterology, 2008, 14, 3338.	1.4	50
138	Pathogenesis and management of pruritus in cholestatic liver disease. Journal of Gastroenterology and Hepatology (Australia), 2012, 27, 1150-1158.	1.4	50
139	Fluoxetine for the Treatment of Fatigue in Primary Biliary Cirrhosis: A Randomized, Double-Blind Controlled Trial. Digestive Diseases and Sciences, 2006, 51, 1985-1991.	1.1	46
140	A Randomized, Placebo-Controlled Clinical Trial of Efficacy and Safety: Modafinil in the Treatment of Fatigue in Patients With Primary Biliary Cirrhosis. American Journal of Therapeutics, 2017, 24, e167-e176.	0.5	46
141	Reliability and Validity of the NIDDK-QA Instrument in the Assessment of Quality of Life in Ambulatory Patients With Cholestatic Liver Disease. Hepatology, 2000, 32, 924-929.	3.6	45
142	Effect of Ursodeoxycholic Acid on Serum Lipids of Patients With Primary Biliary Cirrhosis. Mayo Clinic Proceedings, 1994, 69, 923-929.	1.4	43
143	Human leukocyte antigen Class II associations in serum antimitochondrial antibodies (AMA)-positive and AMA-negative primary biliary cirrhosis. Journal of Hepatology, 2002, 36, 8-13.	1.8	42
144	Design and Endpoints for Clinical Trials in Primary Sclerosing Cholangitis. Hepatology, 2018, 68, 1174-1188.	3.6	42

#	Article	IF	Citations
145	Factors Associated With Prevalence and Treatment of Primary Biliary Cholangitis in United States Health Systems. Clinical Gastroenterology and Hepatology, 2018, 16, 1333-1341.e6.	2.4	42
146	Mycophenolate Mofetil for the Treatment of Primary Biliary Cirrhosis in Patients with an Incomplete Response to Ursodeoxycholic Acid. Journal of Clinical Gastroenterology, 2005, 39, 838.	1.1	41
147	Varices in Early Histological Stage Primary Biliary Cirrhosis. Journal of Clinical Gastroenterology, 2011, 45, e66-e71.	1.1	40
148	Ursodeoxycholic acid in primary sclerosing cholangitis: If withdrawal is bad, then administration is good (right?). Hepatology, 2014, 60, 785-788.	3.6	40
149	An update on cancer risk and surveillance in primary sclerosing cholangitis. Liver International, 2017, 37, 1103-1109.	1.9	40
150	Obeticholic acid for the treatment of primary biliary cholangitis. Expert Opinion on Pharmacotherapy, 2016, 17, 1809-1815.	0.9	39
151	Curcumin in Hepatobiliary Disease: Pharmacotherapeutic Properties and Emerging Potential Clinical Applications. Annals of Hepatology, 2017, 16, 835-841.	0.6	39
152	ÂAlkaline phosphatase normalization is a biomarker of improved survival in primary sclerosing cholangitis. Annals of Hepatology, 2016, 15, 246-53.	0.6	39
153	Incomplete response to ursodeoxycholic acid in primary biliary cirrhosis: is a double dosage worthwhile?. American Journal of Gastroenterology, 2001, 96, 3152-3157.	0.2	38
154	Management of osteoporosis, fat-soluble vitamin deficiencies, and hyperlipidemia in primary biliary cirrhosis. Clinics in Liver Disease, 2003, 7, 901-910.	1.0	38
155	Silymarin in the Treatment of Patients with Primary Sclerosing Cholangitis: An Open-Label Pilot Study. Digestive Diseases and Sciences, 2008, 53, 1716-1720.	1.1	38
156	Obeticholic acid and budesonide for the treatment of primary biliary cirrhosis. Expert Opinion on Pharmacotherapy, 2014, 15, 365-372.	0.9	38
157	Combination Therapy of All-Trans Retinoic Acid With Ursodeoxycholic Acid in Patients With Primary Sclerosing Cholangitis. Journal of Clinical Gastroenterology, 2017, 51, e11-e16.	1.1	38
158	Fatigue in primary biliary cirrhosis. Nature Reviews Gastroenterology and Hepatology, 2010, 7, 313-319.	8.2	37
159	The safety and efficacy of oral docosahexaenoic acid supplementation for the treatment of primary sclerosing cholangitis â€“ a pilot study. Alimentary Pharmacology and Therapeutics, 2012, 35, 255-265.	1.9	37
160	Old and new treatments for primary biliary cholangitis. Liver International, 2017, 37, 490-499.	1.9	37
161	Treatment With Ursodeoxycholic Acid Is Associated With Weight Gain in Patients With Primary Biliary Cirrhosis. Journal of Clinical Gastroenterology, 2003, 37, 183-185.	1.1	36
162	Changing nomenclature for PBC: From â€˜cirrhosisâ€™ to â€˜cholangitisâ€™. Clinics and Research in Hepatology and Gastroenterology, 2015, 39, e57-e59.	0.7	36

#	Article	IF	Citations
163	Long-term outcomes in antimitochondrial antibody negative primary biliary cirrhosis. Scandinavian Journal of Gastroenterology, 2016, 51, 745-752.	0.6	36
164	Impact of inflammatory bowel disease and ursodeoxycholic acid therapy on small-duct primary sclerosing cholangitis. Hepatology, 2007, 47, 133-142.	3.6	35
165	Antimitochondrial Antibodyâ€“Negative Primary Biliary Cirrhosis. Gastroenterology Clinics of North America, 2008, 37, 479-484.	1.0	35
166	Primary biliary cholangitis: 2021 practice guidance update from the American Association for the Study of Liver Diseases. Hepatology, 2022, 75, 1012-1013.	3.6	34
167	Liver Stiffness Measured by Either Magnetic Resonance or Transient Elastography Is Associated With Liver Fibrosis and Is an Independent Predictor of Outcomes Among Patients With Primary Biliary Cholangitis. Journal of Clinical Gastroenterology, 2021, 55, 449-457.	1.1	34
168	The Natural History of Primary Biliary Cirrhosis. Seminars in Liver Disease, 2014, 34, 329-333.	1.8	33
169	Primary biliary cirrhosis in adults. Expert Review of Gastroenterology and Hepatology, 2014, 8, 427-433.	1.4	31
170	Open-label prospective therapeutic clinical trials: oral vancomycin in children and adults with primary sclerosing cholangitis. Scandinavian Journal of Gastroenterology, 2020, 55, 941-950.	0.6	31
171	Complications, symptoms, quality of life and pregnancy in cholestatic liver disease. Liver International, 2018, 38, 399-411.	1.9	30
172	Measurement of Gamma Glutamyl Transferase to Determine Risk of Liver Transplantation or Death in Patients With Primary Biliary Cholangitis. Clinical Gastroenterology and Hepatology, 2021, 19, 1688-1697.e14.	2.4	30
173	Dominant strictures in primary sclerosing cholangitis: A multicenter survey of clinical definitions and practices. Hepatology Communications, 2018, 2, 836-844.	2.0	28
174	Number needed to treat with ursodeoxycholic acid therapy to prevent liver transplantation or death in primary biliary cholangitis. Gut, 2020, 69, 1502-1509.	6.1	28
175	Mycophenolate mofetil for the treatment of primary biliary cirrhosis in patients with an incomplete response to ursodeoxycholic acid. Journal of Clinical Gastroenterology, 2005, 39, 168-71.	1.1	28
176	Pregnancy in a Patient With Primary Sclerosing Cholangitis. Journal of Clinical Gastroenterology, 2002, 35, 353-355.	1.1	27
177	Effects of ursodeoxycholic acid on hepatic inflammation and histological stage in patients with primary biliary cirrhosis. American Journal of Gastroenterology, 1996, 91, 2314-7.	0.2	27
178	Current research on the treatment of primary sclerosing cholangitis. Intractable and Rare Diseases Research, 2015, 4, 1-6.	0.3	26
179	Clinical implications of serial versus isolated biliary fluorescence in situ hybridization (FISH) polysomy in primary sclerosing cholangitis. Scandinavian Journal of Gastroenterology, 2017, 52, 377-381.	0.6	26
180	Effect of pretransplantation ursodeoxycholic acid therapy on the outcome of liver transplantation in patients with primary biliary cirrhosis. Liver Transplantation, 1999, 5, 269-274.	1.9	25

#	Article	IF	Citations
181	Fatigue measurements in patients with primary biliary cirrhosis and the risk of mortality during follow-up. Liver International, 2010, 30, 251-258.	1.9	25
182	Early Cholangiocarcinoma Detection With Magnetic Resonance Imaging Versus Ultrasound in Primary Sclerosing Cholangitis. Hepatology, 2021, 73, 1868-1881.	3.6	25
183	Safety of fibrates in cholestatic liver diseases. Liver International, 2021, 41, 1335-1343.	1.9	25
184	Antibiotics for the Treatment of Primary Sclerosing Cholangitis. American Journal of Therapeutics, 2011, 18, 261-265.	0.5	24
185	Long-term Outcomes of Patients With Primary Biliary Cirrhosis and Hepatocellular Carcinoma. Clinical Gastroenterology and Hepatology, 2012, 10, 182-185.	2.4	24
186	Neoplasia in the ileoanal pouch following colectomy in patients with ulcerative colitis and primary sclerosing cholangitis. Journal of Crohn's and Colitis, 2014, 8, 1294-1299.	0.6	23
187	Efficacy and safety of curcumin in primary sclerosing cholangitis: an open label pilot study. Scandinavian Journal of Gastroenterology, 2019, 54, 633-639.	0.6	23
188	The natural history of abdominal pain associated with primary biliary cirrhosis. American Journal of Gastroenterology, 1994, 89, 1840-3.	0.2	23
189	An update on primary sclerosing cholangitis epidemiology, outcomes and quantification of alkaline phosphatase variability in a population-based cohort. Journal of Gastroenterology, 2020, 55, 523-532.	2.3	22
190	Consensus guidelines: best practices for detection, assessment and management of suspected acute drugâ€induced liver injury occurring during clinical trials in adults with chronic cholestatic liver disease. Alimentary Pharmacology and Therapeutics, 2020, 51, 90-109.	1.9	21
191	Global incidence, prevalence and features of primary sclerosing cholangitis: A systematic review and metaâ€analysis. Liver International, 2021, 41, 2418-2426.	1.9	21
192	Challenges of Cholangiocarcinoma Detection in Patients with Primary Sclerosing Cholangitis. Journal of Analytical Oncology, 2012, 1, 50-55.	0.1	20
193	Clinical management of autoimmune biliary diseases. Journal of Autoimmunity, 2013, 46, 88-96.	3.0	18
194	Oral Vancomycin Therapy in a Child with Primary Sclerosing Cholangitis and Severe Ulcerative Colitis. Pediatric Gastroenterology, Hepatology and Nutrition, 2016, 19, 210.	0.4	18
195	Advances in primary sclerosing cholangitis. The Lancet Gastroenterology and Hepatology, 2016, 1, 68-77.	3.7	18
196	Factors Associated With Progression and Outcomes of Early Stage Primary Biliary Cholangitis. Clinical Gastroenterology and Hepatology, 2020, 18, 684-692.e6.	2.4	17
197	The autologous mixed lymphocyte reaction in primary biliary cirrhosis: Analysis of activation and blastogenesis of autoreactive T lymphocytes. Hepatology, 1988, 8, 1555-1559.	3.6	16
198	Emerging drugs for the treatment of Primary Biliary Cholangitis. Expert Opinion on Emerging Drugs, 2016, 21, 39-56.	1.0	16

#	Article	IF	Citations
199	Update on pharmacotherapies for cholestatic liver disease. Hepatology Communications, 2017, 1, 7-17.	2.0	16
200	Review article: nuclear receptors and liver disease â€“ current understanding and new therapeutic implications. Alimentary Pharmacology and Therapeutics, 2009, 30, 816-825.	1.9	15
201	New Treatment Strategies for Primary Sclerosing Cholangitis. Digestive Diseases, 2011, 29, 113-116.	0.8	15
202	The Microbiome and Primary Sclerosing Cholangitis. Seminars in Liver Disease, 2016, 36, 340-348.	1.8	15
203	Early primary biliary cirrhosis: Just delayed or different?. Hepatology, 1997, 26, 239-241.	3.6	14
204	Association between serum IgE level and adverse clinical endpoints in primary sclerosing cholangitis. Annals of Hepatology, 2014, 13, 384-389.	0.6	14
205	Ursodeoxycholic Acid Treatment Preferentially Improves Overall Survival Among African Americans With Primary Biliary Cholangitis. American Journal of Gastroenterology, 2020, 115, 262-270.	0.2	14
206	A Comparison of Prognostic Scores (Mayo, UK-PBC, and GLOBE) in Primary Biliary Cholangitis. American Journal of Gastroenterology, 2021, 116, 1514-1522.	0.2	14
207	Primary Biliary Cholangitis: 2018 Practice Guidance From the American Association for the Study of Liver Diseases. Clinical Liver Disease, 2020, 15, 1-2.	1.0	13
208	The management of autoimmunity in patients with cholestatic liver diseases. Expert Review of Gastroenterology and Hepatology, 2016, 10, 73-91.	1.4	12
209	Emerging treatments for primary sclerosing cholangitis. Expert Review of Gastroenterology and Hepatology, 2017, 11, 451-459.	1.4	12
210	Conflict of interest policy. Liver Transplantation, 2008, 14, 1-1.	1.3	11
211	Moexipril for Treatment of Primary Biliary Cirrhosis in Patients with an Incomplete Response to Ursodeoxycholic Acid. Digestive Diseases and Sciences, 2010, 55, 476-483.	1.1	11
212	Distinguishing immunoglobulin G4â€“related disease from its pancreatobiliary mimics: Are we there now?. Hepatology, 2016, 64, 340-343.	3.6	11
213	Primary sclerosing cholangitis in children versus adults: lessons for the clinic. Expert Review of Gastroenterology and Hepatology, 2018, 12, 1025-1032.	1.4	11
214	Antimitochondrial Antibodyâ€“Negative Primary Biliary Cholangitis. Clinics in Liver Disease, 2018, 22, 589-601.	1.0	11
215	Current and promising therapy for primary biliary cholangitis. Expert Opinion on Pharmacotherapy, 2019, 20, 1161-1167.	0.9	10
216	The long-term outcomes of patients with immunoglobulin G4-related sclerosing cholangitis: the Mayo Clinic experience. Journal of Gastroenterology, 2020, 55, 1087-1097.	2.3	10

#	Article	IF	Citations
217	Primary Sclerosing Cholangitis, Part 1: Epidemiology, Etiopathogenesis, Clinical Features, and Treatment. Gastroenterology and Hepatology, 2018, 14, 293-304.	0.2	9
218	Low risk of HCC in patients who have PSC and cirrhosis. Nature Reviews Gastroenterology and Hepatology, 2014, 11, 276-277.	8.2	8
219	Primary biliary cirrhosis: safety and benefits of established and emerging therapies. Expert Opinion on Drug Safety, 2015, 14, 1435-1444.	1.0	8
220	Successful response of primary sclerosing cholangitis and associated ulcerative colitis to oral vancomycin may depend on brand and personalized dose: report in an adolescent. Clinical Journal of Gastroenterology, 2021, 14, 684-689.	0.4	8
221	Chronic cholestasis in a young man. Hepatology, 1994, 20, 1351-1355.	3.6	7
222	The metabolic bone disease of primary sclerosing cholangitis. Hepatology, 1991, 14, 257-261.	3.6	7
223	Cancer risk, screening and surveillance in primary sclerosing cholangitis. Minerva Gastroenterologica E Dietologica, 2019, 65, 214-228.	2.2	7
224	Ursodeoxycholic Acid Treatment in Primary Sclerosing Cholangitis. , 2017, , 145-152.		7
225	Association between serum IgE level and adverse clinical endpoints in primary sclerosing cholangitis. Annals of Hepatology, 2014, 13, 384-9.	0.6	7
226	Machine learning in primary biliary cholangitis: A novel approach for risk stratification. Liver International, 2022, 42, 615-627.	1.9	7
227	A pilot study of vidofludimus calcium for treatment of primary sclerosing cholangitis. Hepatology Communications, 2022, 6, 1589-1597.	2.0	7
228	Investigational drugs in phase II clinical trials for primary biliary cholangitis. Expert Opinion on Investigational Drugs, 2017, 26, 1115-1121.	1.9	6
229	Time course of histological progression in primary biliary cirrhosis. Hepatology, 1996, 23, 52-56.	3.6	6
230	Management of primary biliary cirrhosis: From diagnosis to end-stage disease. Current Gastroenterology Reports, 2000, 2, 94-98.	1.1	5
231	Medical treatment for primary sclerosing cholangitis: Risk versus benefit. Hepatology, 2003, 32, 871-872.	3.6	5
232	Potential Association of Doxycycline With the Onset of Primary Sclerosing Cholangitis: A Case Series. American Journal of Therapeutics, 2022, 29, e437-e443.	0.5	5
233	NGM282, an FGF19 analogue, in primary sclerosing cholangitis: A nebulous matter. Journal of Hepatology, 2019, 70, 348-350.	1.8	5
234	Primary Sclerosing Cholangitis, Part 2: Cancer Risk, Prevention, and Surveillance. Gastroenterology and Hepatology, 2018, 14, 427-432.	0.2	4

#	Article	IF	Citations
235	Colchicine and ursodeoxycholic ccid for primary biliary cirrhosis: Emerging results. Gastroenterology, 1995, 108, 1592-1594.	0.6	3
236	Primary biliary cirrhosis. Current Treatment Options in Gastroenterology, 1999, 2, 473-480.	0.3	3
237	Pregnancy in primary sclerosing cholangitis. Gut, 2011, 60, 1027-1028.	6.1	3
238	Editorial: betaretrovirus in biliary epithelia of patients with autoimmune and cryptogenic liver disease. Alimentary Pharmacology and Therapeutics, 2015, 41, 490-490.	1.9	3
239	Dynamic Risk Prediction of Response to Ursodeoxycholic Acid Among Patients with Primary Biliary Cholangitis in the USA. Digestive Diseases and Sciences, 2022, 67, 4170-4180.	1.1	3
240	Chronic cholestasis in a young man. Hepatology, 1994, 20, 1351-1355.	3.6	3
241	Is there a role for tetrathiomolybdate in the treatment of primary biliary cirrhosis?. Translational Research, 2010, 155, 120-122.	2.2	2
242	Heterogeneity of Outcomes Following Liver Transplantation for Primary Sclerosing Cholangitis: Age Matters. Digestive Diseases and Sciences, 2017, 62, 3210-3211.	1.1	2
243	Simplified care-pathway selection for nonspecialist practice. European Journal of Gastroenterology and Hepatology, 2020, Publish Ahead of Print, .	0.8	2
244	Medical Management of Chronic Cholestatic Liver Diseases. Canadian Journal of Gastroenterology & Hepatology, 2000, 14, 93D-98D.	1.8	1
245	The possible link between the thyroid and autoimmune liver diseases: reply. Liver International, 2010, 30, 1240-1241.	1.9	1
246	An overview of current and future therapeutic strategies for the treatment of primary sclerosing cholangitis. Expert Opinion on Orphan Drugs, 2014, 2, 545-556.	0.5	1
247	Novel treatments in primary sclerosing cholangitis. Clinical Liver Disease, 2016, 8, 132-135.	1.0	1
248	Editorial: is proton pump inhibitor use associated with worse outcomes in patients with liver abscesses?. Alimentary Pharmacology and Therapeutics, 2018, 47, 1226-1227.	1.9	1
249	Assessing and managing symptom burden and quality of life in primary sclerosing cholangitis patients. Expert Opinion on Orphan Drugs, 2021, 9, 53-66.	0.5	1
250	Recent developments in the management of idiopathic cholestatic liver disease. Annals of Gastroenterology, 2012, 25, 317-326.	0.4	1
251	Reply: Diagnostic Utility of Chromosome 17 and p16 Abnormalities in Fluorescence In Situ Hybridization Tests in Primary Sclerosing Cholangitis. Hepatology, 2010, 52, 394-395.	3.6	0
252	Targets and investigative treatments for primary biliary cholangitis. Expert Opinion on Orphan Drugs, 2016, 4, 1011-1020.	0.5	0

#	Article	IF	Citations
253	Managing PBC: Expanding the Provider Comfort Zone. Digestive Diseases and Sciences, 2018, 63, 2487-2488.	1.1	0
254	Emerging therapeutic targets for primary sclerosing cholangitis. Expert Opinion on Orphan Drugs, 2018, 6, 393-401.	0.5	0
255	Alan Hofmann (1931â€2021): A career well spent understanding bile acids. Hepatology, 2022, 75, 238-239.	3.6	0
256	Commentary: Primary Sclerosing Cholangitis. , 2015, , 61-63.		0
257	Primary biliary cirrhosis. Revista De GastroenterologÃa De MÃ©xico, 1995, 60, S75-7.	0.4	0
258	Primary sclerosing cholangitis. Revista De GastroenterologÃa De MÃ©xico, 1995, 60, S78-80.	0.4	0
259	Linking medical education and patient care. Minnesota Medicine, 2010, 93, 32, 34.	0.1	0